Literature DB >> 17845256

Why have meta-analyses of randomized controlled trials of the association between non-white-blood-cell-reduced allogeneic blood transfusion and postoperative infection produced discordant results?

E C Vamvakas1.   

Abstract

Intention-to-treat analyses of randomized controlled trials (RCTs) of the association between non-white-blood-cell (WBC)-reduced allogeneic blood transfusion (ABT) and postoperative infection were reported as the reason why meta-analyses of RCTs of this association have produced discordant results. We examined three possible reasons for disagreements between meta-analyses: (i) sources of medical heterogeneity and integration of RCTs despite extreme heterogeneity; (ii) reliance on as-treated (vs. intention-to-treat) comparisons; and (iii) inclusion (or not) of the three most recent RCTs. When nine RCTs reported up to 2002 were combined despite extreme heterogeneity, both intention-to-treat and as-treated comparisons found an association between non-WBC-reduced ABT and postoperative infection [summary odds ratio (OR) = 1.38, 95% confidence interval (CI) 1.03-1.85, P < 0.05; and summary OR = 1.56, 95% CI 1.06-2.31, P < 0.05, respectively]. When 12 RCTs reported up to 2005 were integrated despite extreme heterogeneity, both intention-to-treat and as-treated comparisons found no association of non-WBC-reduced ABT with postoperative infection (summary OR = 1.24, 95% CI 0.98-1.56, P > 0.05; and summary OR = 1.31, 95% CI 0.98-1.75, P > 0.05, respectively). In both analyses, the separate integration of four RCTs transfusing red blood cells (RBCs) or whole blood filtered after storage showed an association between non-WBC-reduced ABT and postoperative infection, whereas the separate integration of six (or nine) RCTs, reported through 2002 or 2005, and transfusing prestorage-filtered RBCs showed no association, whether intention-to-treat or as-treated comparisons were used. Thus, the published meta-analyses have produced discordant results because they did (or did not) investigate medical sources of heterogeneity and did (or did not) include the most recent RCTs. Intention-to-treat and as-treated comparisons produced concordant results.

Entities:  

Mesh:

Year:  2007        PMID: 17845256     DOI: 10.1111/j.1423-0410.2007.00959.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  10 in total

1.  Old blood, new blood or better stored blood?

Authors:  Giancarlo Maria Liumbruno; James P Aubuchon
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 2.  Leucoreduction of blood components: an effective way to increase blood safety?

Authors:  Maria Bianchi; Stefania Vaglio; Simonetta Pupella; Giuseppe Marano; Giuseppina Facco; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-12-16       Impact factor: 3.443

3.  Blood storage duration and biochemical recurrence of cancer after radical prostatectomy.

Authors:  Juan P Cata; Eric A Klein; Gerald A Hoeltge; Jarrod E Dalton; Edward Mascha; Jerome O'Hara; Amanda Russell; Andrea Kurz; Shamgar Ben-Elihayhu; Daniel I Sessler
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

Review 4.  Prevention and control of neglected tropical diseases: overview of randomized trials, systematic reviews and meta-analyses.

Authors:  Shanthi Kappagoda; John P A Ioannidis
Journal:  Bull World Health Organ       Date:  2014-03-13       Impact factor: 9.408

5.  The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses.

Authors:  John P A Ioannidis
Journal:  Milbank Q       Date:  2016-09       Impact factor: 4.911

Review 6.  Reducing noninfectious risks of blood transfusion.

Authors:  Brian M Gilliss; Mark R Looney; Michael A Gropper
Journal:  Anesthesiology       Date:  2011-09       Impact factor: 7.892

Review 7.  Does prolonged storage of red blood cells cause harm?

Authors:  Willy A Flegel; Charles Natanson; Harvey G Klein
Journal:  Br J Haematol       Date:  2014-01-25       Impact factor: 6.998

Review 8.  Transfusion immunomodulation--the case for leukoreduced and (perhaps) washed transfusions.

Authors:  Katie L Lannan; Julie Sahler; Sherry L Spinelli; Richard P Phipps; Neil Blumberg
Journal:  Blood Cells Mol Dis       Date:  2012-09-13       Impact factor: 3.039

9.  Blood transfusion promotes cancer progression: a critical role for aged erythrocytes.

Authors:  Shir Atzil; Michal Arad; Ariella Glasner; Noa Abiri; Roi Avraham; Keren Greenfeld; Ella Rosenne; Benzion Beilin; Shamgar Ben-Eliyahu
Journal:  Anesthesiology       Date:  2008-12       Impact factor: 7.892

10.  Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis.

Authors:  Clément Palpacuer; Karima Hammas; Renan Duprez; Bruno Laviolle; John P A Ioannidis; Florian Naudet
Journal:  BMC Med       Date:  2019-09-16       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.